Fowler J F
Department of Human Oncology, University of Wisconsin Medical School, Madison 53792.
Int J Radiat Oncol Biol Phys. 1990 May;18(5):1261-9. doi: 10.1016/0360-3016(90)90467-x.
It is assumed that initial dose rates of 10-20 cGy/hour and total doses of 1500-2000 cGy, delivered with effective half-lives of a few days, are reasonable starting points for assessing the radiobiological effects of such low and declining dose rates. Such doses might kill 2 or 3 logs of cells out of the 9 or 10 required for tumor eradication; this is well known. The emphasis in this paper is on the change of effectiveness (per Gy) with change in dose rate. Biological effectiveness, in terms of log cell kill per Gy, will be less than that of higher dose rates because there is more time for repair of sublethal radiation injury. This loss in Relative Effectiveness, RE, is unlikely to exceed 20% in most types of tumor cell, compared with conventional external beam radiation schedules. Therefore, a tumor or metastatic deposit that would require 60-70 Gy to sterilize it using conventional radiotherapy with 2 Gy fractions (or traditional radioactive implants at 50 cGy/hr) would require 70-84 Gy at the lower dose rates available from radioimmunotherapy. This is the major dose rate effect and so far we have ignored proliferation. In the dose-rate range of 10-300 cGy/hr in vitro, highly variable depending on type of cell, division might be prevented but not progression through the cell cycle. Additional cell kill is observed because cells accumulate in the radiosensitive G2 phase; this is the inverse dose-rate effect. However, that range of dose rates comes from in vitro experiments where cells are doubling in number every 0.5 to 1 day. In vivo they double more slowly so it is possible that the unpredictable benefit of G2 accumulation, or partial synchrony, could occur at lower dose rates than 10 cGy/hr in human tumors. The dose rates necessary to kill cells at exactly the rate they are proliferating (which of course would not alone eradicate tumors or metastases) can be calculated, if values are assumed for intrinsic radiosensitivity and doubling rate of cells. In median ranges, dose rates of 2-3 cGy/hr should just counteract proliferation. Higher dose rates, maintained for a few days, could cause 2 or 3 logs of cell kill which would be observed as partial regression, as has been reported clinically and in animal experiments.
假定初始剂量率为10 - 20厘戈瑞/小时,总剂量为1500 - 2000厘戈瑞,有效半衰期为几天,这些是评估此类低剂量率和递减剂量率的放射生物学效应的合理起始点。这样的剂量可能会杀死肿瘤根除所需的9或10个对数细胞中的2或3个对数细胞;这是众所周知的。本文的重点是随着剂量率的变化,(每戈瑞的)有效性的变化。就每戈瑞的对数细胞杀伤而言,生物学有效性将低于较高剂量率时的情况,因为亚致死性辐射损伤的修复时间更多。与传统外照射放疗方案相比,在大多数类型的肿瘤细胞中,相对有效性(RE)的这种损失不太可能超过20%。因此,一个肿瘤或转移灶若使用2戈瑞分次的传统放疗(或50厘戈瑞/小时的传统放射性植入物)需要60 - 70戈瑞来使其失活,那么在放射免疫治疗所提供的较低剂量率下则需要70 - 84戈瑞。这就是主要的剂量率效应,到目前为止我们忽略了增殖。在体外10 - 300厘戈瑞/小时的剂量率范围内,高度可变,具体取决于细胞类型,细胞分裂可能会被阻止,但细胞周期的进程不会被阻止。观察到额外的细胞杀伤,因为细胞积聚在放射敏感的G2期;这就是逆剂量率效应。然而,该剂量率范围来自体外实验,其中细胞每0.5到1天数量就会翻倍。在体内它们翻倍得更慢,所以在人类肿瘤中,G2期积聚或部分同步化带来的不可预测的益处可能会在低于10厘戈瑞/小时的剂量率下出现。如果假设细胞的固有放射敏感性和翻倍率的值,就可以计算出以细胞增殖速率精确杀死细胞所需的剂量率(当然,这本身并不能根除肿瘤或转移灶)。在中等范围内,2 - 3厘戈瑞/小时的剂量率应该刚好可以抵消增殖。较高的剂量率维持几天,可能会导致2或3个对数细胞的杀伤,这将表现为部分消退,正如临床和动物实验中所报道的那样。